Hims & Hers Health (NYSE:HIMS) Shares Down 0.5% Following Insider Selling

Hims & Hers Health, Inc. (NYSE:HIMS)’s stock price fell 0.5% during trading on Tuesday after an insider sold shares in the company. The stock traded as low as $21.06 and last traded at $21.51. 1,883,908 shares traded hands during trading, a decline of 72% from the average session volume of 6,817,031 shares. The stock had previously closed at $21.62.

Specifically, Director Lynne Chou O’keefe sold 10,044 shares of the company’s stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $15.52, for a total value of $155,882.88. The sale was disclosed in a document filed with the SEC, which is available at this link. In other Hims & Hers Health news, CFO Oluyemi Okupe sold 98,635 shares of the company’s stock in a transaction that occurred on Thursday, June 6th. The stock was sold at an average price of $21.42, for a total value of $2,112,761.70. Following the sale, the chief financial officer now owns 146,839 shares in the company, valued at approximately $3,145,291.38. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Lynne Chou O’keefe sold 10,044 shares of the company’s stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $15.52, for a total value of $155,882.88. The disclosure for this sale can be found here. Insiders have sold a total of 951,004 shares of company stock worth $16,188,821 over the last quarter. Insiders own 17.71% of the company’s stock.

Analyst Upgrades and Downgrades

HIMS has been the subject of several research analyst reports. Canaccord Genuity Group upped their target price on Hims & Hers Health from $20.00 to $24.00 and gave the stock a “buy” rating in a research note on Wednesday, May 22nd. Seaport Res Ptn reaffirmed a “buy” rating on shares of Hims & Hers Health in a research note on Friday, April 26th. Deutsche Bank Aktiengesellschaft upped their target price on Hims & Hers Health from $14.00 to $16.00 and gave the stock a “hold” rating in a research note on Tuesday, May 7th. Canaccord Genuity Group started coverage on Hims & Hers Health in a research note on Wednesday, April 10th. They issued a “buy” rating and a $20.00 price objective for the company. Finally, Jefferies Financial Group reissued a “hold” rating and issued a $15.00 price objective (down from $17.00) on shares of Hims & Hers Health in a research note on Tuesday, April 16th. Seven equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, Hims & Hers Health has a consensus rating of “Moderate Buy” and a consensus target price of $16.14.

Hims & Hers Health Trading Up 7.8 %

The business has a fifty day moving average of $15.40 and a 200 day moving average of $12.34. The company has a market capitalization of $5.10 billion, a PE ratio of -2,375.00 and a beta of 1.08.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, May 6th. The company reported $0.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.03. The company had revenue of $278.20 million for the quarter, compared to analyst estimates of $270.37 million. Hims & Hers Health had a negative return on equity of 0.70% and a negative net margin of 0.24%. Hims & Hers Health’s revenue for the quarter was up 45.8% compared to the same quarter last year. During the same quarter last year, the company earned ($0.05) EPS. Equities analysts forecast that Hims & Hers Health, Inc. will post 0.18 EPS for the current fiscal year.

Institutional Investors Weigh In On Hims & Hers Health

A number of hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. raised its position in shares of Hims & Hers Health by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 14,310,192 shares of the company’s stock worth $221,379,000 after acquiring an additional 136,907 shares in the last quarter. Forerunner Ventures Management LLC acquired a new stake in shares of Hims & Hers Health during the 4th quarter worth about $86,836,000. Dimensional Fund Advisors LP raised its position in shares of Hims & Hers Health by 9.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,147,927 shares of the company’s stock worth $19,117,000 after acquiring an additional 193,507 shares in the last quarter. Farallon Capital Management LLC raised its position in shares of Hims & Hers Health by 3,890.5% during the 1st quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock worth $25,928,000 after acquiring an additional 1,634,000 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Hims & Hers Health by 1.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,294,759 shares of the company’s stock worth $11,523,000 after acquiring an additional 22,009 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.